← Leaderboards
Anutosh Chakraborty
Univ Of North Carolina Chapel Hill
$4,228,389
Attributed
$5,170,186
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,170,186 · 4
By mechanism
R01$4,669,038 · 3
T32$501,148 · 1
Top collaborators
- John K. Walker2 shared
- Xiaodong Wang2 shared
- Gina L.C. Yosten2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Maya Shalev Styner$2,347,777
- Xiaodong Wang$2,479,253
- Ana Cartaya$74,126
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsDiphosphatesInsulin SensitivityInsulin ResistanceStressEnergy MetabolismMetabolismAdipocytesIn VivoObesityKnockout MiceInositolMetabolicPathway InteractionsMalignant NeoplasmsPreventLinkMediatingProteinsIn VitroInnovationKnock-OutEnzymesOverexpression
Grant awards (13)
Novel IP6K1 inhibitors for treatment of NAFLD/NASH$569,142
R01 · FY2025 · DK
Determining hepatocyte-specific mechanisms by which Ube4A regulates NAFLD/NASH$462,823
R01 · FY2025 · DK · contact PI
Novel IP6K1 inhibitors for treatment of NAFLD/NASH$646,254
R01 · FY2024 · DK
Determining hepatocyte-specific mechanisms by which Ube4A regulates NAFLD/NASH$566,893
R01 · FY2024 · DK · contact PI
Pharmacological Sciences Training Grant$255,280
T32 · FY2024 · GM
Determining hepatocyte-specific mechanisms by which Ube4A regulates NAFLD/NASH$514,249
R01 · FY2023 · DK · contact PI
Pharmacological Sciences Training Grant$245,868
T32 · FY2023 · GM
Inositol hexakisphosphate kinase-1 As a Novel Target in Obesity$340,875
R01 · FY2019 · DK · contact PI
Inositol hexakisphosphate kinase-1 As a Novel Target in Obesity$340,875
R01 · FY2018 · DK · contact PI
Inositol hexakisphosphate kinase-1 As a Novel Target in Obesity$254,646
R01 · FY2017 · DK · contact PI
Inositol hexakisphosphate kinase-1 As a Novel Target in Obesity$109,281
R01 · FY2017 · DK · contact PI
Inositol hexakisphosphate kinase-1 As a Novel Target in Obesity$432,000
R01 · FY2016 · DK · contact PI
Inositol hexakisphosphate kinase-1 As a Novel Target in Obesity$432,000
R01 · FY2015 · DK · contact PI